STAGE III URETHRAL CANCER AJCC V8
Clinical trials for STAGE III URETHRAL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III URETHRAL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III URETHRAL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for bladder cancer patients who Can't take standard chemo
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder cancer that has spread. The trial includes 72 adults whose cancer cannot be treated with the standard cisplatin c…
Matched conditions: STAGE III URETHRAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:24 UTC
-
New combo therapy targets Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…
Matched conditions: STAGE III URETHRAL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:23 UTC
-
New combo aims to tame Immunotherapy's side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: STAGE III URETHRAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Immunotherapy plus chemo shows promise against Tough-to-Treat cancers
Disease control OngoingThis early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…
Matched conditions: STAGE III URETHRAL CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo aims to stall advanced bladder cancer
Disease control OngoingThis study tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from progressing after initial chemotherapy. About 654 adults with advanced bladder, kidney, or ureter cancer that has spread will receive either the combo or avelu…
Matched conditions: STAGE III URETHRAL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Can your genes tell if immunotherapy will work? new study investigates
Knowledge-focused OngoingThis study looks at whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well the immunotherapy drug nivolumab works in people with advanced bladder cancer that has spread. About 6 participants with these gene changes will receive nivolum…
Matched conditions: STAGE III URETHRAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 10:29 UTC